Table 1 Dose Groups and Product Formulations
From: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
Dose Cohorts | Number of patients in Cohort (Patient number) | Peptides loaded/HLA class | Peptide loading method and concentration | DEX dose (expressed as numbers of MHC class II molecules) |
|---|---|---|---|---|
A | 3 (DU 5, 6, 8) | MAGE-A3 (112–120)/class I MAGE-A4 (230–239)/class I MAGE-A10 (254–262)/class I CMV pp65/class II Tetanus toxoid/class II | Indirect (10 μg/mL) Indirect (10 μg/mL) Indirect (10 μg/mL) Indirect (10 μg/mL) Indirect (10 μg/mL) | 0.13 × 10 14 |
B | 5 (DU 24, 39, 44, 50, 63) | MAGE-A3 (112–120)/class I MAGE-A4 (230–239)/class I MAGE-A10 (254–262)/class I CMV pp65/class I MAGE-A3 (247–258)/class II Tetanus toxoid/class II | Direct (10 μg/mL) Direct (10 μg/mL) Direct (10 μg/mL) Direct (10 μg/mL) Indirect (10 μg/mL) Indirect (10 μg/mL) | 0.13 × 10 14 |
C | 4 (DU 49, 73, 81, 83) | MAGE-A3 (112–120)/class I MAGE-A4 (230–239)/class I MAGE-A10 (254–262)/class I MAGE-A3 (247–258)/class II | Direct (100 μg/mL) Direct (100 μg/mL) Direct (100 μg/mL) Indirect (10 μg/mL) | 0.13 × 10 14 |